This module uses fundamental data of Ginkgo Bioworks to approximate the value of its Beneish M Score. Ginkgo Bioworks M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Ginkgo Bioworks Piotroski F Score and Ginkgo Bioworks Altman Z Score analysis.
Ginkgo
Beneish M Score
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Good Will
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Cash And Equivalents
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Current Deferred Revenue
Capital Lease Obligations
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Minority Interest
Probability Of Bankruptcy
At present, Ginkgo Bioworks' Interest Debt Per Share is projected to increase slightly based on the last few years of reporting. The current year's Cash Flow To Debt Ratio is expected to grow to 1.03, whereas Short and Long Term Debt Total is forecasted to decline to about 163.1 M. At present, Ginkgo Bioworks' Inventory Turnover is projected to increase significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 8.46, whereas Price To Sales Ratio is forecasted to decline to 12.41.
At this time, it appears that Ginkgo Bioworks Holdings is an unlikely manipulator. The earnings manipulation may begin if Ginkgo Bioworks' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Ginkgo Bioworks executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Ginkgo Bioworks' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Ginkgo Bioworks' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Ginkgo Bioworks' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Ginkgo Bioworks in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Ginkgo Bioworks' degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Other Operating Expenses
1.38 Billion
At present, Ginkgo Bioworks' Other Operating Expenses is projected to increase significantly based on the last few years of reporting.
Ginkgo Bioworks ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ginkgo Bioworks' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ginkgo Bioworks' managers, analysts, and investors.
Environmental
Governance
Social
About Ginkgo Bioworks Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ginkgo Bioworks Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ginkgo Bioworks using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ginkgo Bioworks Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.89)
Revenue Per Share
4.291
Quarterly Revenue Growth
0.606
Return On Assets
(0.21)
Return On Equity
(0.64)
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.